No Data
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
Investors Three-year Losses Continue as Asymchem Laboratories (Tianjin) (SZSE:002821) Dips a Further 4.3% This Week, Earnings Continue to Decline
Featured announcements | Kanzhun revenue increased 19% year-on-year in the third quarter; China Taibao's original premium income during the year exceeded 410 billion yuan
Xinyi Glass and Xinyi Auto Glass (Hong Kong) signed a 2024 glass supply agreement; CGN Energy completed a cumulative total of 17,684.1 gigawatt-hours of power generation in the first 11 months, an increase of 1.7% over the previous year.
Gloria Ying: Some directors, senior management and core technical and business personnel increased their holdings of the company by 23.2638 million yuan
Gelonghui reported on December 11 that Asymchem Laboratories (002821.SZ) announced that as of the date of this announcement, the implementation period of this Shareholding plan has passed halfway. Some Directors, senior management, and other core technical and business personnel have cumulatively increased their holdings of the company’s shares by 344,194 shares through the centralized bidding trading system of the Shenzhen Exchange, accounting for 0.0936% of the current total share capital of the company, with a total increase amount of 23.2638 million yuan.
Bearish landing? Hong Kong stocks in the pharmaceutical sector collectively strengthen with wuxi apptec rising over 8%.
① How much impact did the biological safety legislation have on domestic pharmaceutical stocks previously? ② How do industry insiders view the subsequent development of the biological legislation?
Hong Kong stock concept tracking | The biocontrol bill was not included in the latest version of NDAA. Institutions are bullish on the bottom opportunities in the CXO sector (with concept stocks attached).
On December 7, 2024, local time in the USA, the US Congressional Armed Services Committees in both the House and the Senate released the final agreement text of the 2025 National Defense Authorization Act (NDAA), which incorporates proposals from both chambers.
Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) Stock Catapults 26% Though Its Price And Business Still Lag The Market
